Acambis wins vaccine technology patent case against Bavarian Nordic

By Lisa Kerner

Charlotte, N.C., Sept. 7 - An International Trade Commission administrative law judge ruled in favor of Acambis plc and invalidated all of the patent claims asserted by Bavarian Nordic A/S related to Modified Vaccinia Ankara technology, which both companies use in the manufacture of smallpox vaccines.

Bavarian Nordic filed its complaint with the commission in August 2005, alleging infringement by Acambis of two of its Modified Vaccinia Ankara patents, and filed additional complaints with the District Court of Delaware and the Commercial Court in Vienna, Austria.

Acambis then filed an opposition to Bavarian Nordic's patent in May.

Vaccine development company Acambis is based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.